Goserelin


Synthetic GnRH agonist (decapeptide)

A synthetic GnRH agonist provided as a subcutaneous depot implant; approved for prostate cancer, breast cancer, and endometriosis.

Abstract

Goserelin (5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-O-(1,1-dimethylethyl)-D-seryl-L-leucyl-L-arginyl-2-(carbamoylimino)hydrazinyl-L-prolinamide; CAS 65807-02-5; molecular formula C59H84N18O14; molecular weight 1269.41) is a synthetic GnRH agonist decapeptide developed at ICI (now AstraZeneca) and approved by the FDA in 1989 under the trade name Zoladex. Mechanism is identical to leuprolide and triptorelin. Approved for advanced prostate cancer, advanced breast cancer in pre- and perimenopausal women, endometriosis, and uterine leiomyomata. The implant delivery is preferred in some clinical settings for compliance and steady plasma profile. Used as a reference GnRH agonist with depot implant delivery.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph